Table 1 Clinicopathologic characteristics of serous ovarian cancer
From: Age is associated with prognosis in serous ovarian carcinoma
Characteristic | ≥ 65 years N (%) | < 65 years N (%) | p # |
|---|---|---|---|
Baseline CA-125 (U/mL, meida, range) | 960 (7–34,000) | 840 (7–30,900) | 0.55 |
Body Mass Index (mean SD) | 24.1 (3.1) | 25.4 (3.8) | 0.04 |
Grade | |||
 High | 106 (96.4) | 178 (87.3) | 0.02 |
 Low | 4 (3.6) | 26 (12.7) | |
FIGO* stage | |||
 I | 3 (2.7) | 5 (2.5) | 0.84 |
 II | 8 (7.3) | 10 (4.9) | |
 III | 75 (68.2) | 146 (71.6) | |
 IV | 24 (21.8) | 43 (21.1) | |
ECOG PS* | |||
 0 | 44 (40.0%) | 104 (51.0%) | 0.03 |
 1 | 47 (42.7%) | 83 (40.7%) | |
  ≥ 2 | 19 (17.3%) | 17 (8.3%) | |
Primary treatment | |||
 NAC* | 31 (28.2%) | 30 (14.7%) | 0.00 |
 PDS | 50 (45.5%) | 151 (74.0%) | |
 Chemotherapy only | 18 (16.4%) | 8 (3.9%) | |
 No Treatment | 11 (10.0%) | 15 (7.4%) | |
Surgical residual†| |||
 Optimal | 44 (54.3%) | 123 (68.0%) | 0.04 |
 Suboptimal | 33 (40.7%) | 48 (26.5%) | |
 Unknown | 4 (5.0%) | 10 (5.5%) | |
Recurrence free interval (months) | |||
  ≤ 12 | 34 (47.2%) | 56 (35.7%) | 0.13 |
  > 12 | 38 (52.8%) | 101 (64.3%) | |